Innova Captab Limited filed unaudited financial results for the quarter and half year ended 30th September, 2026 pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Financial Performance - Q2 FY27 vs Q2 FY26

  • Revenue from Operations: ₹496.3 crores (vs ₹380.4 crores), growth of 30.5% YoY
  • EBITDA: ₹72.4 crores (vs ₹56.1 crores), growth of 29.2% YoY
  • EBITDA Margin: 14.6% (vs 14.7%, decline of 10 bps)
  • PAT: ₹42.4 crores (vs ₹29.7 crores), growth of 43.0% YoY
  • PAT Margin: 8.5%

Financial Performance - H1 FY27 vs H1 FY26

  • Revenue from Operations: ₹967.2 crores (vs ₹731.9 crores), growth of 32.1% YoY
  • EBITDA: ₹147.5 crores (vs ₹112.6 crores), growth of 31.0% YoY
  • EBITDA Margin: 15.3% (vs 15.4%, decline of 10 bps)
  • PAT: ₹86.5 crores (vs ₹60.7 crores), growth of 42.6% YoY
  • PAT Margin: 8.9%

Management Commentary

Mr. Vinay Lohariwala, Managing Director, commented that the performance underscores the continued strength of the company's diversified business model and disciplined execution across business operations. The company witnessed healthy business momentum across its CDMO and Branded Generics businesses, supported by a diversified product portfolio and deeper customer engagement. The focus remains on operational excellence, manufacturing efficiency, and quality. The company is unequivocally focussed on continued Jammu ramp-up alongside further strengthening of manufacturing capabilities.

Forward Outlook

The company remains committed to strengthening its CDMO positioning, expanding its branded generics presence, and ramping up manufacturing capacities. Management expressed confidence in sustaining long-term growth and value for stakeholders through strategic roadmap focusing on timely and disciplined capital allocation decisions.

Company Background

Innova Captab Limited is a leading pharmaceutical company with presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution, marketing, and exports. The company operates five state-of-the-art manufacturing facilities consisting of 9 independent blocks, accredited by leading global regulatory bodies like WHO-GMP, EU-GMP, UK-MHRA, and PIC/s. The CDMO business serves over 350 clients in India and international markets.